[Pharmacological action and clinical results of Omarigliptin (MARIZEV® tablet), a novel dipeptidyl peptidase-4 inhibitor for once-weekly treatment of Type 2 diabetes]

Nihon Yakurigaku Zasshi. 2017;149(3):128-137. doi: 10.1254/fpj.149.128.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Animals
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl-Peptidase IV Inhibitors / administration & dosage*
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacokinetics
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology*
  • Drug Administration Schedule
  • Drug Evaluation
  • Drug Evaluation, Preclinical
  • Heterocyclic Compounds, 2-Ring / administration & dosage*
  • Heterocyclic Compounds, 2-Ring / pharmacokinetics
  • Heterocyclic Compounds, 2-Ring / pharmacology*
  • Humans
  • Hypoglycemic Agents
  • In Vitro Techniques
  • Mice
  • Pyrans / administration & dosage*
  • Pyrans / pharmacokinetics
  • Pyrans / pharmacology*

Substances

  • 2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine
  • Dipeptidyl-Peptidase IV Inhibitors
  • Heterocyclic Compounds, 2-Ring
  • Hypoglycemic Agents
  • Pyrans